The Never-ending fight against cancer is in full-force and the results have been on the brighter side of things. Some of the most advanced cancer-fighting medications are upon humanity, and they’re creating dramatic results by saving lives at a higher rate. Dr. Clay Siegall, CEO of Seattle Genetics, is one of the most loved figures in this dynamic field of work. He has a long history of working in the medical industry, and he has worked with many high profile names. This includes the National Institute of Health, the National Cancer Institute and Bristol Myers Squibb. The guy has served on the Boards of Directors for Alder BioPharmaceuticals and Ultragenyx.
The success of Seattle Genetics comes from multiple avenues, whether it’s great leadership, strategic marketing or from licensing. Thanks to his great business sense, Siegall has been able to strike-up multiple strategic license deals with some of the industry’s most prominent names. This includes:
With this licensing, the company can distribute the advanced medications to other areas around the globe. This means that 65 different countries around the globe can now use Seattle Genetics’ ADCETRIS drug. ADCETRIS is an antibody drug conjugate, and it is far superior to any other cancer fighting drug of today. It has helped the company bring in over $350 million in which it has helped the company’s stock triple in a span of five years. That’s right! Seattle Genetics is outperforming everyone else at a consistent rate. The 21st century is Seattle Genetics’ playground as the company has 20 more advanced drugs in its pipeline of success.
The great thing about all of this news is that Dr. Clay Siegall is in control of it all. This well-accomplished doctor is setting new trends, and he is changing the status quo.
Dr. Clay Siegall is the Chief Executive Officer at Seattle Genetics. He is also the founder of the company. Based in Bothell City in the State of Washington, Seattle Genetics is a leading biotechnology solutions provider that dedicates itself to the development of targeted therapy medication for disease types that have not seen significant mortality improvements in several years. Dr. Clay Siegall is a well-educated individual especially in his field of expertise. Dr. Siegall graduated from the University of Maryland with a Bachelor’s of Science in Zoology. He also holds a Doctor of Philosophy in genetics from George Washington University.
Ever since he founded Seattle Genetics on July 15, 1997, Dr. Siegall has consciously and progressively steered the firm to the summit of the targeted therapy industry. They developed the first FDA-approved antibody-drug conjugate, which now has multiple approved indications. They have also developed a stable pipeline of drugs and an array of strategic partnerships with manufacturers of medicines such as Bayer, Genentech, Pfizer among several others just to mention a few. This, in essence, shows that Dr. Siegall is not done yet, going into the future, Seattle Genetics has positioned itself to be the go-to industry leaders when it comes to matters cancer treatment by use of targeted therapy drugs.
Thanks to Dr. Siegall’s able leadership, Seattle Genetics has grown from a small startup with just a minimal team of scientists to be one of the most sought-after authorities in the cancer research industry. Motivated and inspired by the love of medicine from a tender age, Dr. Siegall was always fascinated by the use of the power of technology to overcome disease and as a result saving lives. His interest was further drawn to cancer treatment while studying Zoology at the University of Maryland after one of his family members got ill and almost died not from cancer but from the brutal treatment regimen of chemotherapy. Dr. Siegall believes that the days of using systematic chemotherapies are over and that it is about time we welcomed the most efficient and effective and more tolerable way of cancer treatment – the use of targeted therapy drugs.
Dr. Clay Siegall, the Chief Executive Officer and Founder of Seattle Genetics started this company with the intentions of developing targeted therapy medication for diseases that had not shown any improvement for years. Dr. Clay has a Bachelor of Science in Zoology and a Ph.D. in Genetics from The University of Maryland and George Washington University respectively. Seattle Genetic began in 1998 and has been working tirelessly towards getting targeted therapies. It has so far come up with over twenty drugs and the first antibody drug conjugate, ADC, which has been approved by the FDA. Dr. Clay Siegall has led the company into partnerships with manufacturers of drugs such as Genentech, Bayer, and Pfizer among others.
Dr. Clay has also managed to grow the company into a major player in the research of cancer. The company has been well positioned to keep growing in the industry through the number of drugs they currently have in the pipeline and the role they are playing in increasing the indications that could potentially be used in making drugs for crucial diseases. Dr. Siegall expresses his hope in finding targeted drugs that will be effective in the treatment of critical diseases such as cancer. Dr. Clay Siegall has always had a passion for medicine. He believes that people should not be condemned to brutal methods of treatment while they are trying to get better. His close family member who suffered from cancer had a great role in Dr. Clay’s engagement and interest to find solutions for such diseases.
At some point in the operations of Seattle Genetics, the company faced some challenges but they were able to pull through. Through this experience, Dr. Clay was able to work smarter towards his goals and so far success has come his way. He has put in place a team of experienced sales executives who assist in selling their products and creating awareness in the industry. The fact that the products they offer are unique and effective, selling is made easier since the product can speak for itself. Dr. Clay Siegall attributes the success of his company to hard work. He believes that as long as anyone works hard towards their goals, they will be successful.